

AD-A189 586

THE ROLE OF ENDORPHINS IN THE PATHOPHYSIOLOGY OF
HEMORRHAGIC AND ENDOTOXIC (U) IOWA UNIV IOWA CITY COLL
OF MEDICINE N J GURLL ET AL 15 MAR 85


1/1


UNCLASSIFIED

DAND17-88-C-0094

F/G 6/5

NL





RESOLUTION TEST CHART

DTIC FILE COPY

AD _____

THE ROLE OF ENDORPHINS IN THE PATHOPHYSIOLOGY
OF HEMORRHAGIC AND ENDOTOXIC SHOCK IN
THE SUBHUMAN PRIMATE

Annual and Final Report

Nelson J. Gurll, M.S.
David G. Reynolds, Ph.D.
Thomas Vargish, M.D.
Carl V. Gisolfi, Ph.D.

March 15, 1985

Supported by

U.S. Army Medical Research and Development Command
Fort Detrick, Frederick, Maryland 21701-5012

Contract No. DAMD17-80-C-0094
DAMD17-81-C-1177

The University of Iowa
College of Medicine
Iowa City, Iowa 52242

DTIC
ELECTE
DEC 14 1987
S H D

Supersedes AD-A162483

Approved for public release; distribution unlimited

The findings in this report are not to be construed as an
official Department of the Army position unless so designated
by other authorized documents

87

12

8

100

AD-A189506

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1a. REPORT SECURITY CLASSIFICATION Unclassified		1b. RESTRICTIVE MARKINGS	
2a. SECURITY CLASSIFICATION AUTHORITY		3. DISTRIBUTION / AVAILABILITY OF REPORT Approved for public release; Distribution unlimited	
2b. DECLASSIFICATION / DOWNGRADING SCHEDULE		5. MONITORING ORGANIZATION REPORT NUMBER(S)	
4. PERFORMING ORGANIZATION REPORT NUMBER(S)		7a. NAME OF MONITORING ORGANIZATION	
6a. NAME OF PERFORMING ORGANIZATION University of Iowa College of Medicine	6b. OFFICE SYMBOL (If applicable)	7b. ADDRESS (City, State, and ZIP Code)	
6c. ADDRESS (City, State, and ZIP Code) Iowa City, Iowa 52242		9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD17-80-C-0094 and DAMD17-81-C-1177	
8a. NAME OF FUNDING / SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command	8b. OFFICE SYMBOL (If applicable)	10. SOURCE OF FUNDING NUMBERS	
8c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21701-5012		PROGRAM ELEMENT NO. 62772A	PROJECT NO. 3S1- 62772A874
		TASK NO. AB	WORK UNIT ACCESSION NO. 134
11. TITLE (Include Security Classification) The Role of Endorphins in the Pathophysiology of Hemorrhagic and Endotoxic Shock in the Subhuman Primate			
12. PERSONAL AUTHOR(S) Nelson J. Gurll, M.D.; David G. Reynolds, Ph.D.; Thomas Vargish, M.D.; Carl V. Gisolfi, Ph.D.			
13a. TYPE OF REPORT Annual and Final	13b. TIME COVERED FROM 80/6/1 to 85/3/15	14. DATE OF REPORT (Year, Month, Day) 1985 March 15	15. PAGE COUNT 65
16. SUPPLEMENTARY NOTATION Annual (for the period 1 September 1982 through 15 March 1985) Final (for the period 1 June 1980 through 15 March 1985)			
17. COSATI CODES		18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD	GROUP	shock, endorphins, naloxone, hemorrhage, endotoxemia, primate shock, opiate receptors, thyrotropin-releasing hormone, TRH, pathophysiology of shock	
06	05		
06	11		
19. ABSTRACT (Continue on reverse if necessary and identify by block number) In order to investigate the pathophysiological role of endogenous morphine-like substances (endorphins) in shock, we studied cynomolgus monkeys and dogs subjected to hemorrhagic or endotoxic shock. Blockade of opiate receptors with naloxone improved cardiovascular function and survival in both species and both models but requires correction of acidosis and hypothermia. Shock is associated with elevations in plasma levels of endorphins. Using different sites of injection, and various anatomical and pharmacological ablations, we have shown that naloxone's beneficial effects in hemorrhagic shock are due to potentiation of the effect of released catecholamines on cardiac opiate receptors. The myocardial depression found in shock is due to an endorphin-mediated attenuation of catecholamine activity on the heart. We believe this is mediated by interaction with cardiac receptors and is expressed via G-protein activation of adenylate cyclase and cyclic-AMP. This hypothesis needs to be tested by biochemical determination of these substances, and our observations need to be extended to endotoxic shock. Nevertheless, naloxone and other			
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT ☐ UNCLASSIFIED/UNLIMITED ☒ SAME AS RPT ☐ DTIC USERS		21. ABSTRACT SECURITY CLASSIFICATION Unclassified	
22a. NAME OF RESPONSIBLE INDIVIDUAL Mrs. Virginia Miller		22b. TELEPHONE (Include Area Code) 301/663-7325	22c. OFFICE SYMBOL SGRD-RMI-S

antiendorphin substances may be important in the treatment of shock by reversing one of the important pathophysiological mechanisms of cardiovascular depression.

SUMMARY

In order to investigate the pathophysiological role of endogenous morphine-like substances (endorphins for short) in shock, we studied cynomolgus monkeys and dogs subjected to hemorrhagic or endotoxic shock.

Blockade of opiate receptors with naloxone improved cardiovascular function (mean arterial pressure, cardiac output, and myocardial contractility) in both species and both models but requires correction of acidosis and hypothermia. Shock is associated with elevations in plasma levels of β -endorphin and β -lipotropin. Using different sites of injection and various pharmacological

and anatomical ablations, we have shown that naloxone's beneficial effects in hemorrhagic shock are due to potentiation of the effect of released

catecholamines on cardiac opiate receptors. The myocardial depression found in shock is due to an endorphin-induced attenuation of catecholamine effects on the heart. We believe this is mediated by interaction with cardiac

receptors and is expressed via G-protein activation of adenylate cyclase and cyclic-AMP. This hypothesis needs to be tested by biochemical determination of these substances, and our observations need to be extended to endotoxic

shock. Nevertheless, naloxone and other antienkephalin substances may be important in the treatment of shock by reversing one of the important

pathophysiological mechanisms of cardiovascular depression. *Keywords: Physiology*

Received 10 November 1977

Dist	Avail and/or Special	1-1
Availability Codes		
By	Distribution	
Justification		
NTIS CRA&I	☒	
DTIC TAB	☐	
Unannounced	☐	
Justification	☐	
Accession For		

SUMMARY

In order to investigate the pathophysiological role of endogenous morphine-like substances (endorphins for short) in shock, we studied cynomolgus monkeys and dogs subjected to hemorrhagic or endotoxic shock. Blockade of opiate receptors with naloxone improved cardiovascular function (mean arterial pressure, cardiac output, and myocardial contractility) in both species and both models but requires correction of acidosis and hypothermia. Shock is associated with elevations in plasma levels of β -endorphin and β -lipotropin. Using different sites of injection and various pharmacological and anatomical ablations, we have shown that naloxone's beneficial effects in hemorrhagic shock are due to potentiation of the effect of released catecholamines on cardiac opiate receptors. The myocardial depression found in shock is due to an endorphin-induced attenuation of catecholamine effects on the heart. We believe this is mediated by interaction with cardiac receptors and is expressed via G-protein activation of adenylate cyclase and cyclic-AMP. This hypothesis needs to be tested by biochemical determination of these substances, and our observations need to be extended to endotoxic shock. Nevertheless, naloxone and other antiendorphin substances may be important in the treatment of shock by reversing one of the important pathophysiological mechanisms of cardiovascular depression. *Keywords: thyrotrop*

Accession For	
NTIS CRA&I	☒
DTIC TAB	☐
Unannounced	☐
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

FOREWORD

In conducting the research described in this report, the investigators adhered to the "Guide for the Care and Use of Laboratory Animals", prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHEW Publication No. (NIH) 78-23, revised 1978).

TABLE OF CONTENTS

Summary.....	3
Foreword.....	4
Body of Report.....	7
a) Problem and Background.....	7
b) Approach.....	8
c) Results: Endotoxemia in Monkeys.....	9
d) Results: Hemorrhage in Monkeys.....	9
e) Results: Central Nervous System Injections.....	10
f) Results: Corticosteroid-Naloxone Interactions.....	10
g) Results: Adrenalectomy.....	11
h) Results: Autonomic Nervous System Involvement.....	12
i) Results: Blood Flow.....	13
j) Results: Naltrexone, Nalbuphine and TRH.....	14
k) Results: Importance of Timing.....	14
l) Results: Other Studies on Mechanisms and Site of Action.....	15
m) Discussion.....	16
n) Conclusions.....	19
o) Recommendations.....	19
Illustrations and Tables.....	20
Table I: Plasma β -endorphin (β -EP) and b-lipotropin (β -LPH) in monkey endotoxemia	20
Table II: Plasma β -endorphin (β -EP) and β -lipotropin (β -LPH) in monkey hemorrhage shock.....	20
Table III: Whole blood histamine in monkey hemorrhagic shock.....	21
Table IV: Effects of intracerebral infusion of naloxone	21
Table V: Effect of surgical and pharmacological autonomic intervention.....	22
Table VI: Effect of adrenal denervation and ganglionic blockade with chlorisondamine.....	22
Table VII: Regional blood flow distribution during hemorrhage hypotension in the dog.....	23
Figure 1: Primate Endotoxin Shock.....	24
Figure 2: Primate Endotoxin Shock.....	24
Figure 3: Primate Hemorrhagic Shock.....	25
Figure 4: Primate Hemorrhagic Shock.....	25
Figure 5: Primate Hemorrhagic Shock.....	26
Figure 6: Primate Hemorrhagic Shock.....	26
Figure 7: Primate Hemorrhagic Shock.....	27
Figure 8: Primate Hemorrhagic Shock.....	27
Figure 9: Primate Hemorrhagic Shock.....	28
Figure 10: Primate Hemorrhagic Shock.....	29
Figure 11: Primate Hemorrhagic Shock.....	29
Figure 12.....	30
Figure 13a.....	30
Figure 13b.....	30
Figure 14.....	31

Figure 15.....	32
Figure 16: Uncompensated Hemorrhagic Shock, Survival.....	32
Figure 17: Canine Hemorrhagic Shock.....	33
Figure 18: Canine Hemorrhagic Shock.....	33
Figure 19: Canine Hemorrhagic Shock.....	34
Figure 20.....	35
Figure 21.....	35
Figure 22.....	35
Figure 23.....	35
Figure 24.....	36
Figure 25.....	36
Figure 26.....	37
Figure 27.....	37
Figure 28.....	38
Figure 29.....	38
Figure 30: TRH in Primate Hemorrhagic Shock.....	39
Figure 31: TRH in Primate Hemorrhagic Shock.....	39
Figure 32: Effect of TRH in Primate Endotoxic Shock.....	40
Figure 33: Effect of TRH in Primate Endotoxic Shock.....	40
Figure 34: Delayed Naloxone Treatment in Hemorrhagic Shock.....	41
Figure 35: Delayed Naloxone Treatment in Hemorrhagic Shock.....	41
Figure 36: Delayed Naloxone Treatment in Hemorrhagic Shock.....	42
Figure 37: Delayed Naloxone Treatment in Hemorrhagic Shock.....	42
Figure 38: Intracerebroventricular Naloxone.....	43
Figure 39: Intracerebroventricular Naloxone.....	43
Figure 40: Intracerebroventricular Naloxone.....	44
Figure 41: Intracerebroventricular Naloxone.....	45
Figure 42: Intracerebroventricular Naloxone.....	45
Figure 43: Intracerebroventricular Naloxone.....	46
Figure 44: Intrathecal Naloxone.....	47
Figure 45: Intrathecal Naloxone.....	47
Figure 46: Intrathecal Naloxone.....	48
Figure 47.....	49
Figure 48.....	50
Literature Cited.....	51
Chronological Bibliography.....	55
Personnel Supported in This Contract.....	64
Distribution List.....	65

BODY OF REPORT

a) Problem and Background

Shock due to hemorrhage, trauma, and sepsis remains an important threat to the health and welfare of the soldier in war. Even during peacetime, septic and hypovolemic shock are frequent and important causes of morbidity and mortality in the civilian and military populations. These shock states do not always respond to appropriate therapies suggesting the involvement of other pathophysiological mechanisms and hence other treatment options. The exigencies of the battlefield situation and the availability of rapid evacuation make the use of simple, rapid, on-the-scene anti-shock therapies highly desirable.

Endogenous morphine-like substances (endorphins) are elevated in the plasma in response to stress (1). Endogenous and exogenous opiates depress the cardiovascular system when given intravenously or into the central nervous system (2). The possible involvement of endorphins in the pathophysiology of shock was initially evaluated by Holaday and Faden using rodent models of hemorrhagic and endotoxic shock. Opiate receptor blockade with naloxone improved mean arterial pressure and pulse pressure in rats after hypovolemic hemorrhage (3) or the injection of endotoxin to induce shock (4). This was associated with increased survival in hemorrhage but not in endotoxemia. Subsequently, we showed increased mean arterial pressure, cardiac output and myocardial contractility in canine hemorrhagic (5) and endotoxic shock (6). We also demonstrated improved survival; naloxone converted a 100% lethal hemorrhagic model to 100% survival and an 80% lethal endotoxic shock model to 80% survival.

These results were then extended to humans by others and reported as letters to the editor (7) or uncontrolled, non-randomized trials (8,9). A very recent randomized trial showed no benefit to the use of naloxone in human septic shock (10), but the doses of naloxone used were quite low compared to those found to be effective in rodents, dogs (3-6) and monkeys (vide infra). We chose, instead, to study the doses required, the efficacy, and any side effects of naloxone in a subhuman primate, the cynomolgus monkey. Primates are closer to man than other species studied, and their responses would be better to study before extensive human use. Once we established effectiveness and dosages, we investigated mechanisms using dogs because of the number of animals required.

b) Approach

Cynomolgus monkeys or dogs were lightly anesthetized and instrumented to measure mean arterial pressure (MAP), cardiac output (CO), heart rate (HR), pulmonary arterial pressures, and myocardial contractility (LV dp/dt max). Shock was induced by the intravenous injection of *E. coli* endotoxin or by bleeding into a reservoir to achieve and maintain MAP at 45 mmHg. The animals were treated i.v. with either naloxone 2 mg/kg bolus plus 2 mg/kg*hr infusion for 4 hours or 0.9% NaCl in equivalent volumes when MAP reached 75 mmHg in endotoxemia or after 1 hr of hemorrhage (MAP 45 mmHg). Shed blood was reinfused 1 hr later in the hemorrhage model. These experiments (or slight modifications thereof) were also done after pharmacological or surgical ablation of various components of the neurohumoral responses to shock. Naloxone was also given directly into the central nervous system or the coronary artery to sort out central nervous system from peripheral

cardiac actions. Stereoisomers of naloxone, other opiate receptor antagonists like naltrexone and nalbuphine, and other anti-endorphin substances (namely TRH) were also used.

c) Results: Endotoxemia in monkeys (n=12)

Naloxone significantly increased MAP by 25-30 mmHg over saline treated controls ($p < .02$ by analysis of variance, ANOVA, Figure 1). Left ventricular contractility was higher in naloxone treated monkeys (3.6×10^3 mmHg/sec) than in controls (2.4×10^3 mmHg/sec, $p < .01$ by ANOVA). Naloxone improved LV dp/dt max by 800 mmHg/sec compared to no change with saline ($p < .02$ by ANOVA, Figure 2). There were no differences between naloxone and saline treatment in CO, stroke volume, HP, peripheral vascular resistance, temperature or metabolic measurements. All of the naloxone-treated animals were alive at 48 hours but only 1/6 saline treated controls ($p < .05$ by Fisher's exact test). Plasma levels of β -endorphin and its precursor β -lipotropin rose 4-5-fold and were not affected by treatment (Table I).

d) Results: Hemorrhage in monkeys (n=22)

In the first group of 10 monkeys we could not find a difference in cardiovascular responses between naloxone and saline treatment (Figures 3 and 4). We noted that the naloxone treated animals were acidotic (Figure 5) and colder (Figure 6) than saline-treated animals before treatment. Furthermore, analysis of the MAP responses (as a pressure time product) showed that these responses were affected by temperature and acid-base balance. Acidosis attenuated the pressure x time product in response to naloxone (Figure 7); cold attenuated the plasma β -endorphin response to stress (Figure 8) and the pressure x time product in response to naloxone (Figure 9).

When acidosis and hypothermia were treated or prevented, the monkeys responded to naloxone (n=6) with significant increases in MAP (Figure 10) and LV dp/dt max (Figure 11) compared to no response to saline (n=6). This response increased survival with 5/6 naloxone-treated monkeys alive at 24 hr versus 2/6 saline-treated controls (p<.05). The one naloxone-treated monkey that did not survive at 24 hrs had an iatrogenic death due to a left ventricular catheter-induced myocardial injury. Plasma β -endorphin and β -lipotropin rose 4-5-fold (Table II) and were uninfluenced by treatment. Whole blood histamine levels were unaffected by shock (Table III).

e) Results: Central nervous system injections

Injection of an enkephalin analogue D-ala²-met⁵-enkephalinamide (DAME) into the IIIrd ventricle of conscious monkeys produced bradycardia and hypotension (Figure 12) which were dose-dependent and attenuated by naloxone (Figure 13). Microinjection of DAME into stereotactically implanted areas from the diencephalon to the medulla in normotensive unanesthetized monkeys reduced blood pressure and (inconsistently) heart rate. Injection of naloxone into these DAME-sensitive sites when the animals were anesthetized and subjected to hypovolemic shock, however, failed to increase blood pressure by more than 5 mmHg (Table IV).

f) Results: Corticosteroid-naloxone interactions (n=77)

Dexamethasone and methylprednisolone are putatively beneficial in canine hemorrhagic shock (11). However, these steroids at their maximally effective dosages were not as effective as naloxone when given in our canine hemorrhagic shock model. Indeed, dexamethasone or methylprednisolone at maximally effective doses actually decreased the

beneficial effects of naloxone on hemodynamics and survival. This was true whether blood was returned to the animal (Figure 14) or not (Figures 15 and 16). These steroids were slightly beneficial but not nearly so as naloxone. We postulated that large doses of these steroids were preventing endorphin release. Hence, naloxone, having less endorphin to block, would appear to be less effective.

g) Results: Adrenalectomy (n=23)

Since corticosteroids seemed to have an important interaction with naloxone and because the adrenal contains endorphins, we treated dogs with naloxone or saline one week after adrenalectomy when their plasma endorphin levels were quite high (due to loss of negative feedback by corticosteroids on the pituitary release of β -endorphin). We expected to find enhanced responses to naloxone because of the high plasma endorphin levels. Adrenalectomy, however, completely abolished the MAP and CO responses and markedly attenuated the LV dp/dt max response to naloxone. The full naloxone response could be restored by physiological doses of hydrocortisone 45 minutes before naloxone (Figures 17-19). The adrenal would not appear to be the source of endorphins producing cardiovascular depression in shock. Moreover, naloxone's effectiveness in shock requires an intact adrenal; the factor lost by adrenalectomy appears to be adrenocortical since corticosteroid restore naloxone's effectiveness. Cortisol is required for production (12), stability (13), and receptor binding (14) of catecholamines. Therefore, we thought that there was an endorphin-catecholamine interaction in the peripheral vasculature or the heart which resulted in depression during hemorrhagic shock which was unmasked by naloxone. This idea led to the following series of experiments in dogs.

h) Results: Autonomic nervous system involvement

Naloxone causes a transient decrease in HR and sustained increases in MAP, CO, and LV dp/dt max in canine hemorrhage. The role of the autonomic nervous system was investigated by means of cardiac denervation and pharmacological blockade (n=50). The transient bradycardia was prevented by β -adrenergic receptor blockade or cardiac denervation. The sustained hemodynamic responses were unaffected by cardiac denervation (Figure 20). They were, however, attenuated significantly by either α - or β -adrenergic blockade (phenoxybenzamine or metoprolol, respectively) and potentiated by cholinergic receptor blockade with methylatropine (Figure 21). In these and most subsequent figures, the results are shown as the mean net naloxone effect which is the difference over 30 minutes between the mean response to naloxone and the mean response to saline. Cardiac denervated dogs experienced a tachycardia in response to naloxone which was blocked by β -adrenergic blockade with metoprolol. Naloxone had no effect on plasma catecholamine levels (Table V). The sustained cardiovascular responses to naloxone were the result of a parasympathetic stimulation which modestly attenuated an adrenergic component. The adrenergic stimulation of the heart after naloxone appeared to result from existing adrenergic stimulation and not sympathoadrenal discharge.

We tested the hypothesis that naloxone potentiated the effects of neurally and adrenally released catecholamines (n=60). Catecholamine release was attenuated by a combination of surgical adrenal denervation and pharmacological ganglionic blockade with chlorisondamine (Table VI). Adrenal denervation or chlorisondamine alone attenuated the cardiovascular responses to naloxone in hemorrhage. Denervation and

chlorisondamine in combination completely blocked the mean net naloxone effect which could be completely restored by infusion α - and β -adrenergic agonists at a constant rate prior to naloxone treatment (Figure 22).

We thought that naloxone's potentiation of released catecholamines was primarily on the heart. Naloxone or its inactive stereoisomer were given intravenously (i.v.) or directly into the coronary artery (i.c.) in dogs anesthetized and subjected to hemorrhagic shock. Naloxone 2 mg/kg i.v. or 0.2 mg/kg i.c. significantly improved MAP, CO, and LV dp/dt (Figure 23). Saline or naloxone 0.2 mg/kg i.v. were without beneficial effects. The hemodynamic responses to naloxone i.c. were dose-dependent and stereospecific. We concluded that naloxone's beneficial effects in canine hemorrhagic shock were due to its action at stereospecific cardiac opiate receptors.

We repeated some of these crucial experiments in monkeys (n=20). Ablation of catecholamine responses by adrenalectomy and chlorisondamine completely prevented the increase in MAP and LV dp/dt max due to naloxone in hemorrhage. The usual response to naloxone was restored by infusion of α - and β -adrenergic agonists (Figures 24 and 25).

i) Results: Blood flow

Normovolemic (n=10) and hypovolemic (n=10) dogs were given either saline or naloxone. Naloxone had no effect on the regional blood flow distribution as measured by microspheres in normovolemia. In contrast, naloxone significantly increased blood flow to the heart, intestine, liver (arterial) and adrenal glands when given during

hypovolemic shock (Table VII). These results show increased perfusion of vital organs as a result of improved cardiac action.

j) Results: Naltrexone, nalbuphine, and TRH

We also investigated the use of other agents in shock. The longer acting opiate receptor antagonist naltrexone also improves cardiovascular hemodynamics and survival in canine hemorrhagic shock (Figures 26-29). These results are dose-dependent and support the view that opiate-receptors and/or endorphins are involved in the shock-induced cardiovascular depression by satisfying one of the criteria for opiate involvement (15), namely effectiveness of another opiate antagonist. Naloxone potentially might increase pain perception so we investigated the effectiveness of thyrotropin-releasing hormone (TRH) in primate shock. TRH is a physiological antiendorphin with effects opposite to those of the endorphins without affecting pain perception or binding to opiate receptors (16,17). TRH increases MAP and LV dp/dt max in primate hemorrhagic (Figures 30 and 31) and endotoxemic shock (Figures 32 and 33). These cardiovascular responses were associated with increased survival in hemorrhage but not endotoxemia. The mixed opiate receptor agonist/antagonist nalbuphine relieves pain and yet reverses the cardiovascular depression in canine hemorrhagic shock (Figures 26-29). Survival was also improved. These canine studies were done for a private contractor. However, primate studies done under our Army Contract showed no improvement in hemodynamics or survival.

k) Results: Importance of timing

Delay in naloxone treatment (n=9, versus saline controls n=9) by only 30 min in canine hemorrhage resulted in more modest increases in

MAP (Figure 34), CO (Figure 35), LV dP/dt max (Figure 36) and survival than usual (5). On the other hand, in experiments not covered by this contract, naloxone pre-treatment had some unique effects on endotoxin-induced cardiovascular effects and pathology: it prevented the typical bloody diarrhea, maintained superior mesenteric arterial blood flow and blunted the pulmonary arterial and portal venous hypertensive responses. Survival was also increased to a similar extent (LD_{80} to LD_{20}) as when naloxone was given 15 min after endotoxin without affecting bloody diarrhea or these cardiovascular parameters (6).

1) Results: Other studies on mechanisms and sites of action

Catheters were placed into the central nervous system of dogs. Naloxone (n=5) perfused intracerebroventricularly at 0.1 mg/kg failed to improve MAP (Figure 38), CO (Figure 39) or LV dP/dt max (Figure 40) compared to artificial CSF (n=5) in canine hemorrhage. In contrast, this same dose and route of administration of naloxone (n=5) increased these cardiovascular parameters (Figures 41-43) significantly compared to artificial CSF (n=5) in canine endotoxic shock. Naloxone (n=5) given intrathecally into the cisterna magna failed to have significant cardiovascular effects compared to CSF alone (n=5) in our canine hemorrhagic shock model (Figures 44-46).

The exogenous opioid morphine depresses cardiac function in a dose-dependent and naloxone reversible way (18). A portion of this cardiovascular depression involved histamine release because it was blocked by antihistamines working at the H_1 and H_2 receptors. There were also some direct cardiac depressant effects independent of histamine release which were identified using cardiopulmonary bypass in dogs to separate cardiac and peripheral vascular effects (19).

Opiates failed to release histamine when injected into the intact rat or following incubation with rat peritoneal mast cells, a rich source of histamine. On the other hand, opiates did increase plasma levels of epinephrine and norepinephrine three- to fivefold which was naloxone-blockable and -reversible (19).

m) Discussion

Naloxone improves cardiovascular function and survival in canine and primate hemorrhagic and endotoxemic shock. Our results in primate shock indicate its possible usefulness in human shock but at much higher doses than have been previously reported (in letters to the editor) (reviewed in 7) to be beneficial in human septic or cardiogenic shock. In two uncontrolled, nonrandomized trials naloxone was shown to be effective when given to humans in shock (8,9). These two articles differ in the doses of naloxone used with neither one achieving the dosages we have found to be maximally effective in our primate models. The two studies also differed in that steroids were shown to have no effect by Groeger (9) and a detrimental effect on the hemodynamic response to naloxone by Peters (8). The latter observation would be more consistent with our observations. However, some steroid is necessary for the full naloxone response. Hence some of Peters' "adrenocorticopenic patients" may not have responded because they had had hypophysectomy whereas others in this group merely had received large doses of corticosteroid. Groeger also showed that delay in treatment decreases the effectiveness of naloxone which agrees with our results and those of others (20).

The most recent publication on the human use of naloxone (10) shows no significant cardiovascular effects with doses of naloxone with

which we would not have found an effect in monkeys. These authors also failed to note body temperature and acid-base balance, which we have shown clearly to be important in the naloxone response. After our initial report (21), others have shown that ambient and body temperature are important determinants of the naloxone response in canine endotoxemia (22) and hemorrhagic shock (23) respectively. We would maintain that the ambient temperature effect is mediated by a response in body temperature based upon our results as well as inspection of these authors' results (22).

Our pharmacological and surgical dissection of the naloxone response points to a peripheral cardiac opiate receptor site of cardiovascular depression in canine hemorrhagic shock and its reversal by naloxone. Naloxone appears to potentiate existing adrenergic stimuli at the heart by unmasking endorphin mediated depression. A unifying hypothesis would be an endorphin-catecholamine interaction at the cardiac β -adrenergic receptor and G-proteins. Such an interaction has been demonstrated for morphine and prostaglandins in vivo and in vitro. It is manifested through G-protein activation of adenylate cyclase with biochemical expression through cyclic AMP (Figure 47). Cyclic-AMP then phosphorylates key proteins important to intracellular calcium metabolism and myocardial excitation-relaxation coupling (and ultimately myocardial contractility). These ideas are shown in Figure 48 with known components indicated by asterisks. Such biochemical correlations of physiological interactions are presently being explored in our laboratory. Endorphins elevated in shock attenuate beneficial catecholamine effects and this attenuation is unmasked by naloxone. This supersensitivity to catecholamines may explain some of the side-effects

of naloxone, especially hypertension (24) and arrhythmias (25). Naloxone may also increase catecholamine release in certain situations, and this result should dictate extreme care in its clinical use.

Endotoxic shock appears to involve different naloxone-sensitive mechanisms than hemorrhagic shock. Endotoxemia results in a depression in central sympathetic nerve activity as measured in splanchnic nerves. Naloxone reverses this depression and enhances activity in the splanchnic nerves (26). Central nervous system injection of naloxone has been shown to improve cardiovascular parameters which are then lost in hypophysectomized rats subjected to endotoxemia (27) or hemorrhage (28). However, adrenal atrophy may have resulted due to hypophysectomy and prevented the naloxone response. Others have shown that intracerebroventricular perfusion of naloxone prevents endotoxin-induced decreases in cardiovascular function (29). We have shown that intracerebroventricular perfusion of naloxone fails to increase MAP, CO, or LV dp/dt max in canine hemorrhagic shock but does improve these cardiovascular parameters in endotoxemic shock. Intrathecally administered naloxone similarly fails to improve cardiovascular function in canine hemorrhage. These results in toto would be consistent with different sites for naloxone's effectiveness in hemorrhage and endotoxemia, peripheral cardiac in the former and central nervous system in the latter. By analogy, these sites are also where endorphins depress cardiovascular function in these respective shock paradigms. We need to investigate endotoxemic shock pharmacologically and surgically like we did hemorrhagic shock to exclude possible overlap in mechanisms.

Naloxone appears to be a safe and beneficial agent in the treatment of shock. Other agents like naltrexone, nalbuphine and TRH are available and seem to be effective. Their theoretical advantages have not clearly been established.

n) Conclusions

1. Naloxone improves mean arterial pressure, cardiac output, myocardial contractility, and survival in canine and primate endotoxic and hemorrhagic shock.
2. The site of cardiovascular depression by opiates and its reversal by naloxone appears to be at stereospecific opiate receptors on the heart in hemorrhage. Naloxone potentiates the effects of existent catecholamine activity on the heart by blocking endorphin attenuation of the adrenergic effect.
3. Naltrexone, nalbuphine and TRH are also effective anti-endorphin substances in shock.

c) Recommendations

1. Continue to pursue controlled randomized clinical trials of naloxone in human shock.
2. Investigate the biochemical correlations predicted by our hypothesis, i.e., adenylate cyclase and cyclic-AMP activity in the heart subject to catecholamines and opiates in various combinations.
3. Investigation of mechanisms of cardiovascular depression by opiates in endotoxemic shock by direct intracoronary injection of naloxone and by adrenalectomy and ganglionic blockade followed by infusion of α - and β -adrenergic agonists.

Table I: Plasma α -endorphin (α -EP) and β -lipotropin (β -LPH) in monkey endotoxemia as measured by radioimmunoassay (values in pg/ml)

	Group	Baseline	Treatment=T	T+30 min	End
α -EP	Saline	201 $\pm$ 99	521 $\pm$ 118	781 $\pm$ 142	450 $\pm$ 107
	Naloxone	170 $\pm$ 93	605 $\pm$ 118	936 $\pm$ 203	479 $\pm$ 100
β -LPH	Saline	28 $\pm$ 28	373 $\pm$ 166	844 $\pm$ 293	450 $\pm$ 154
	Naloxone	131 $\pm$ 131	685 $\pm$ 292	972 $\pm$ 428	453 $\pm$ 219

Table II: Plasma α -endorphin (α -EP) and β -lipotropin (β -LPH) in monkey hemorrhage shock as measured by radioimmunoassay (values in pg/ml)

	Group	Baseline	0	60	90	300
α -EP	Saline	382 $\pm$ 125	1072 $\pm$ 187	1171 $\pm$ 265	1289 $\pm$ 122	583 $\pm$ 228
	Naloxone	230 $\pm$ 64	661 $\pm$ 47	895 $\pm$ 142	988 $\pm$ 164	476 $\pm$ 82
β -LPH	Saline	396 $\pm$ 164	1374 $\pm$ 364	674 $\pm$ 168	1936 $\pm$ 498	790 $\pm$ 249
	Naloxone	108 $\pm$ 42	617 $\pm$ 133	798 $\pm$ 246	2316 $\pm$ 1193	615 $\pm$ 212

Table III: Whole blood histamine in monkey hemorrhagic shock as measured by radioenzymatic assay (results in ng/ml)

Group	-60	0	Time, min		180	210
			60	120		
Experimental	13±2	17±2	15±5	16±3	25±6	33±6
Normal literature value 19±9						

Table IV: Effects of intracerebral infusion of naloxone (nal) into multiple opioid-sensitive sites on mean arterial pressure (MAP) during primate hemorrhagic shock

Animal	Total nal in 60', nm	MAP (mmHg)			Survival
		Control	Post-hem	Max Δ	
1	0.587	96	45	+20	+
2	0.176	100	45	+ 5	+
3	1.121	108	45	+12	-
4	0.856	100	45	0	-
5	1.835	100	45	+ 5	-
6	0.920	50	45	+18	-

Table V: Effect of surgical and pharmacological autonomic intervention on plasma catecholamines in canine hemorrhagic shock as measured by radioenzymatic assay (baseline values in pg/ml, rest in mcg/ml)

Intervention	Time	Treatment	Epinephrine	Norepinephrine	Dopamine
Surgical	Baseline		68±35	234±41	114±48
	Shock		18.9±3.4	6.5±0.9	1.6±0.3
	+30 min	Saline	26.5±10.7	8.0±0.7	2.2±0.2
		Naloxone	15.8±2.6	7.9±2.4	1.8±0.4
Pharmacological	Baseline		58±8	213±134	57±50
	Shock	Saline	19.3±3.7	8.6±2.8	1.4±0.2
		Metoprolol	21.1±7.0	5.2±1.3	1.0±0.2
		Phenoxy- benzamine	9.4±1.5	4.2±0.5	1.0±0.2
		Both	14.1±3.5	9.7±4.2	1.1±0.3
		Methylatropine	15.6±3.7	2.9±0.3	0.2±0.7

Table VI: Effect of adrenal denervation (AD) and ganglionic blockade with chlorisondamine (CHL) on plasma catecholamines in canine hemorrhagic shock (baseline values in pg/ml, rest in mcg/ml; also as % of sham AD post-hemorrhage in parentheses)

Group	Epinephrine	Norepinephrine	Dopamine
Sham AD baseline	274±236	180±48	45±29
Post-hemorrhage	18.8±3.8 (100%)	4.2±0.6 (100%)	0.8±0.1 (100%)
AD	2.3±0.2 (12%)	1.2±0.2 (30%)	0.15±0.03 (18%)
CHL	2.1±0.9 (11%)	0.9±0.2 (22%)	0.14±0.02 (18%)
AD+CHL	0.14±0.06 (1%)	0.49±0.06 (12%)	0.04±0.02 (4%)

Table VII: Regional blood flow distribution (ml/min/100 gm) during hemorrhage hypotension in the dog

	Baseline	Shock	Change after Treatment with		
			Saline	Naloxone	p
Heart	169±14	128±19	24±25	118±18	.015
Adrenal	356±41	196±28	-24±55	283±47	.003
Intestine	117±21	29±5	-13±7	15±5	.012
Liver	33±13	16±3	-5±6	18±5	.011
Kidney	865±66	135±18	-2±53	102±53	.204
Brain	81±8	64±8	-7±7	3±5	.257




Figure 1




Figure 2

PRIMATE HEMORRHAGIC SHOCK




Figure 3

PRIMATE HEMORRHAGIC SHOCK




Figure 4




Figure 5




Figure 6

PRIMATE HEMORRHAGIC SHOCK




Figure 7

PRIMATE HEMORRHAGIC SHOCK




Figure 8

PRIMATE HEMMORHAGIC SHOCK




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13a




Figure 13b




Figure 14




Figure 15

UNCOMPENSATED HEMORRHAGIC SHOCK, SURVIVAL




Figure 16

CANINE HEMORRHAGIC SHOCK
Bilateral Adx / MAP





Figure 17
CANINE HEMORRHAGIC SHOCK
Bilateral Adx / C.O.



CANINE HEMORRHAGIC SHOCK
 Bilateral Adx / cp. d*




Figure 19




Figure 20



Figure 21




Figure 22




Figure 23




Figure 24




Figure 25




Figure 26




Figure 27




Figure 28




Figure 29

TRH IN PRIMATE HEMORRHAGIC SHOCK




Figure 30.

TRH IN PRIMATE HEMORRHAGIC SHOCK




Figure 31

EFFECT OF TRH IN PRIMATE ENDOTOXIC SHOCK




Figure 32

EFFECT OF TRH IN PRIMATE ENDOTOXIC SHOCK




Figure 33




Figure 34




Figure 35




Figure 36




Figure 37

INTRACEREBROVENTRICULAR NALOXONE IN CANINE HYPOVOLEMIC SHOCK




Figure 38

INTRACEREBROVENTRICULAR NALOXONE IN CANINE HYPOVOLEMIC SHOCK




Figure 39

INTRACEREBROVENTRICULAR NALOXONE IN CANINE HYPOVOLEMIC SHOCK




Figure 40

INTRACEREBROVENTRICULAR NALOXONE IN CANINE ENDOTOXEMIC SHOCK




Figure 41

INTRACEREBROVENTRICULAR NALOXONE IN CANINE ENDOTOXEMIC SHOCK




Figure 42

INTRACEREBROVENTRICULAR NALOXONE IN CANINE ENDOTOXEMIC SHOCK




Figure 43

INTRATHECAL NALOXONE IN CANINE HYPOVOLEMIC SHOCK




Figure 44

INTRATHECAL NALOXONE IN CANINE HYPOVOLEMIC SHOCK






Figure 45

INTRATHECAL NALOXONE IN CANINE HYPOVOLEMIC SHOCK



TIME, min

Figure 46



H_s = STIMULATORY HORMONE
 β -adrenergic agonists
 Dopamine
 Prostaglandins
 Peptide Hormones

H_i = INHIBITORY HORMONE
 Opioids

GTP = GUANOSINE TRIPHOSPHATE
 ATP = ADENOSINE TRIPHOSPHATE

GDP = GUANOSINE DIPHOSPHATE
 cAMP = CYCLIC ADENOSINE MONOPHOSPHATE

[R] = HORMONE RECEPTOR
 s = STIMULATORY i = INHIBITORY

(G) = GUANINE NUCLEOTIDE-BINDING PROTEIN
 s = STIMULATORY i = INHIBITORY
 α = α SUBUNIT β = β SUBUNIT

(C) = ADENYLATE CYCLASE

$(+)$ = STIMULATION

$(-)$ = INHIBITION

Figure 47




Figure 42

LITERATURE CITED

1. Guillemin R, Vargo T, Minick S, Ling N, Rivier C, Vale W, Bloom F. β -Endorphin and adrenocorticotropin are secreted concomitantly by the pituitary gland. *Science* 1977; 197:1367-1369.
2. Gurll NJ. Endorphins in endotoxin shock. In: Hinshaw LB, ed. *Pathophysiology of Endotoxin*. Amsterdam: Elsevier Science Publishers, 1985:299-337.
3. Faden AI, Holaday JW. Opiate antagonists: a role in the treatment of hypovolemic shock. *Science* 1979; 205:317-318.
4. Holaday JW, Faden AI. Naloxone reversal of endotoxin hypotension suggests role of endorphins in shock. *Nature (London)* 1978; 275:450-451.
5. Vargish T, Reynolds DG, Gurll NJ, Lechner RB, Holaday JW, Faden AI. Naloxone reversal of hypovolemic shock in dogs. *Circ Shock* 1980; 7:31-38.
6. Reynolds DG, Gurll NJ, Vargish T, Lechner RB, Faden AI, Holaday JW. Blockade of opiate receptors with naloxone improves survival and cardiac performance in canine endotoxic shock. *Circ Shock* 1980; 7:39-48.
7. Gurll NJ. Naloxone in endotoxic shock: experimental models and clinical perspective. *Adv Shock Res* 1983; 10:63-71.
8. Peters WP, Friedman PA, Johnson MW, Mitch WE. Pressor effect of naloxone in septic shock. *Lancet* 1981; 1:529-532.
9. Groeger JS, Carlon GC, Howland WS. Naloxone in septic shock. *Crit Care Med* 1983; 11:650-654.

10. DeMaria A, Jefferson JJ, Grindlinger GA, Craven DE, McIntosh TK, McCabe WR. Naloxone versus placebo in treatment of septic shock. *Lancet* 1985; 1:1363-1365.
11. Vargish T, Turner CS, Bond RF, Bagwell CE, James PM. Dose-response relationships in steroid therapy for hemorrhagic shock. *Amer Surg* 1977; 43:30-39.
12. Wurtman RJ, Pohorecky LA, Baliga BS. Adrenocortical control of the biosynthesis of epinephrine and proteins in the adrenal medulla. *Pharmacol Rev* 1972; 24:411-426.
13. Kalsner S. Mechanisms of hydrocortisone potentiation of responses to epinephrine and norepinephrine in rabbit aorta. *Circ Res* 1969; 24:383-395.
14. Besse JC, Bass AD. Potentiation by hydrocortisone of responses to catecholamines in vascular smooth muscle. *J Pharmacol Exp Ther* 1966; 154:224-238.
15. Sawynok J, Pinsky C, LaBella FS. Minireview of the specificity of naloxone as an opiate antagonist. *Life Sci* 1979; 25:1621-1632.
16. Holaday JW, Tseng L-F, Loh H, Li CH. Thyrotropin-releasing hormone antagonizes beta-endorphin hypothermia and catalepsy. *Life Sci* 1978; 22:1537-1544.
17. Holaday JW, D'Amato RJ, Faden AI. Thyrotropin-releasing hormone improves cardiovascular function in experimental endotoxic and hemorrhagic shock. *Science* 1981; 213:216-218.
18. Lind RE, Reynolds DG, Ganes EM, Jenkins JT. Morphine effects on cardiovascular performance. *Am Surg* 1981; 47:107-111.
19. Gurll NJ, Reynolds DG, Polansky D, Elliott D. Unpublished observations.

20. Faden AI, Holaday JW. Naloxone treatment of endotoxic shock: stereospecificity of physiologic and pharmacologic effects in the rat. *J Pharmacol Exp Ther* 1980; 212:441-447.
21. Gurli NJ, Reynolds DG, Vargish T, Ganes E. Body temperature and acid-base balance determine cardiovascular responses to naloxone in primate hemorrhagic shock. *Fed Proc* 1982; 41:1135.
22. Janssen WF, Pugh JL, Lutherer LO. Reduced ambient temperature blocks the ability of naloxone to prevent endotoxin-induced hypotension. *Adv Shock Res* 1982; 7:117-124.
23. Horton JW, Tuggle DW, Kiser RS. Effect of temperature on naloxone treatment in canine hemorrhagic shock. *Circ Shock* 1984; 14:251-265.
24. Tanaka GY. Hypertensive reaction to naloxone. *J Amer Med Assoc* 1974; 228:25.
25. Michaelis LL, Hickey PR, Clark TA, Dixon WM. Ventricular irritability associated with the use of naloxone hydrochloride. *Ann Thorac Surg* 1974; 18:608-614.
26. Koyama S, Santiesban HL, Ammons WS, Manning JW. The effects of naloxone on the peripheral sympathetics in cat endotoxin shock. *Circ Shock* 1983; 10:7-13.
27. Davis SD, McDonald WJ, Kendall JW, Potter DM. Endotoxin shock prevented by naloxone in intact but not hypophysectomized rats. *Proc Soc Exp Biol Med* 1984; 175:380-385.
28. Holaday JW, O'Hara M, Faden AI. Hypophysectomy alters cardiorespiratory variables: central effects of pituitary endorphins in shock. *Am J Physiol* 1981; 241:H479-H485.

29. Janssen HF, Lutherer LO. Ventriculocisternal administration of naloxone protects against several hypotension during endotoxin shock. Brain Res 1980; 194:608-612.

CHRONOLOGICAL BIBLIOGRAPHY

Abstracts

1. N. J. Gurll, R. Lechner, D. G. Reynolds, et al.: The effects of naloxone in canine endotoxic shock. Fed. Proc. 38:1262, 1979.
2. N. Gurll and J. Harmon: Blockade of histamine H_1 and H_2 receptors does not prevent increase in cation permeability due to bile salt. Gastroenterology 76:1146, 1979.
3. N. Gurll and D. G. Reynolds: Histamine receptors in the canine gastric circulation. Gastroenterology 76:1146, 1979.
4. T. Vargish, R. B. Lechner, D. G. Reynolds, N. J. Gurll, A. Faden, and J. W. Holaday: Naloxone reversal of hypovolemic shock in dogs. Circ. Shock 6:181, 1979.
5. D. G. Reynolds, R. B. Lechner, N. J. Gurll, and T. Vargish: Opiate receptor blockade improves cardiac performance in hemorrhagic shock. Physiologist 22:106, 1979.
6. N. Gurll, R. Lechner, D. Reynolds, and T. Vargish: Specific opiate receptor blockade improves cardiac performance and survival in canine hypovolemic shock. Physiologist 22:49, 1979.
7. N. J. Gurll, R. Lechner, T. Vargish, and D. G. Reynolds: Endorphins and opiate receptors are involved in myocardial depression of canine hemorrhagic shock. Clin. Res. 28:8A, 1980.
8. N. J. Gurll, R. Lechner, T. Vargish, and D. G. Reynolds: Dose-dependent naltrexone improvement of cardiovascular function and survival suggests opiate receptors involved in pathophysiology of canine hemorrhagic shock. Clin. Res. 28:17A, 1980.

9. N. Gurll, R. Lechner, D. Reynolds, and J. Jenkins: Autonomic innervation in the cardiovascular responses to naloxone in hypovolemic shock. Fed. Proc. 39:975, 1980.
10. N. Gurll, D. Reynolds, R. Lechner, and T. Vargish: The role of endorphins and opiate receptors in the cardiovascular depression of hypovolemic shock. Proc. Int. Union Physiol. Sci. 14:453, 1980.
11. R. B. Lechner, N. J. Gurll, D. G. Reynolds, and T. Vargish: The opiate receptor antagonist naltrexone improves cardiovascular function and survival in hemorrhagic shock. Circ. Shock 7:200, 1980.
12. N. J. Gurll, D. G. Reynolds, R. E. Lind, and J. T. Jenkins: The efficacy of naloxone in splanchnic ischemic shock. Physiologist 23:36, 1980.
13. J. G. Allison, R. Ankenbauer, N. Gurll, and D. Reynolds: Enkephalins fail to stimulate acid secretion by isolated bullfrog gastric mucosa. Clin. Res. 29:30A, 1981.
14. T. Vargish, E. M. Ganes, D. G. Reynolds, N. J. Gurll, and S. A. Lutz: The combined effects of naloxone and methylprednisolone in canine hemorrhagic shock. Clin. Res. 28:814A, 1981.
15. T. Vargish, E. M. Ganes, D. G. Reynolds, N. J. Gurll, and S. A. Lutz: The combined effects of dexamethasone and naloxone in uncompensated canine hemorrhagic shock. Clin. Res. 29:20A, 1981.
16. S. A. Lutz, T. Vargish, D. G. Reynolds, E. M. Ganes, and N. J. Gurll: Steroid and naloxone interaction in canine hemorrhagic shock. Circ. Shock 8:212, 1981.
17. M. D. Owen, C. V. Gisolfi, D. G. Reynolds, and N. J. Gurll: Effect of D-ala²-met⁵-enkephalinamide (DAME) administered

intracerebroventricularly on selected cardiovascular responses in the non-human primate. *Circ. Shock* 8:189, 1981.

18. N. J. Gurll, D. G. Reynolds, T. Vargish, S. A. Lutz, and E. Ganes: Primate endotoxemic shock reversed by opiate receptor blockade with naloxone. *Physiologist* 24:118, 1981.
19. S. Anuras, A. Shaw, M. D. Schuffler, S. Shirazi, N. J. Gurll, and F. A. Mitros: Familial visceral myopathy - a heterogeneous disease. *Am. J. Gastroenterol.* 76:168, 1981.
20. N. J. Gurll, D. G. Reynolds, T. Vargish, and E. Ganes: Body temperature and acid-base balance determine cardiovascular responses to naloxone in primate hemorrhagic shock. *Fed. Proc.* 41:1135, 1982.
21. S. Anuras, F. A. Mitros, A. Shaw, M. D. Schuffler, A. Milano, S. Shirazi, N. Gurll, and J. B. Green: Familial visceral myopathy, studies of five families. *Gastroenterology* 82:1009, 1982.
22. M. L. Patton, N. G. Gurll, D. G. Reynolds, T. Vargish, and E. M. Ganes: Adrenalectomy abolishes the naloxone effect in hemorrhagic shock. *Circ. Shock* 9:178, 1982.
23. R. E. Hetland, E. M. Ganes, D. G. Reynolds, N. J. Gurll, and T. Vargish: Naloxone in extended uncompensated hemorrhagic shock. *Circ. Shock* 9:174, 1982.
24. N. J. Gurll, D. G. Reynolds, T. Vargish, and E. Ganes: Primate hemorrhagic shock responds to naloxone. *Circ. Shock* 9:189, 1982.
25. N. J. Gurll, D. G. Reynolds, T. Vargish, and E. Ganes: Implication of endorphins in primate hemorrhagic shock. *Langenbecks Archiv. fur Chirurgie* 357:233-234, 1982.

26. E. Ganes, N. J. Gurll, D. G. Reynolds, and T. Vargish: Pre-treatment with naloxone (NAL) attenuates the cardiovascular effects of endotoxic shock in dogs. *Physiologist* 25:308, 1982.
27. D. G. Reynolds, N. J. Gurll, J. Holaday, and E. Ganes: Thyrotropin-releasing hormone (TRH) in primate endotoxic shock. *Physiologist* 25:309, 1982.
28. N. J. Gurll, D. G. Reynolds, J. Holaday, and E. Ganes: Improved cardiovascular function and survival using thyrotropin-releasing hormone (TRH) in primate hemorrhagic shock. *Physiologist* 25:342, 1982.
29. N. J. Gurll, D. G. Reynolds, T. Vargish, E. Ganes, and J. Holaday: Endorphins mediate cardiovascular (CV) depression in primate shock which is reversible with naloxone (NAL) or thyrotropin releasing hormone (TRH). *Proc. Int. Union Physiol. Sci.* 15:209, 1983.
30. L. B. Hunt, D. G. Reynolds, N. J. Gurll, and E. M. Ganes: The efficacy of an opiate antagonist/analgesic drug in canine hemorrhagic shock. *Circ. Shock* 10:235, 1983.
31. R. B. Lechner, N. J. Gurll, D. G. Reynolds, and M. J. Brody: Adrenergic mediation of the naloxone response in shock. *Circ. Shock* 10:235, 1983.
32. B. Fallon, S. Quinlan, N. Gurll: Urological problems associated with primary hyperparathyroidism. Presented at American Urological Association meeting, but not published.
33. R. B. Lechner, N. J. Gurll, D. G. Reynolds, and M. J. Brody: Effects of cardiac denervation on the response to naloxone in canine hemorrhagic shock. *Physiologist* 26:A-75, 1983.

34. R. B. Lechner, N. J. Gurll, D. G. Reynolds, and M. J. Brody:
Effects of naloxone on regional blood flow in hypovolemic and normovolemic dogs. Fed. Proc. 43:415, 1984.
35. K. C. Kregel, C. V. Gisolfi, D. G. Reynolds, and N. J. Gurll:
Intracerebral effects of D-ala₂-met-enkephalinamide injection on systolic blood pressure of the unanesthetized cynomolgus monkey. Fed. Proc. 43:1026, 1984.
36. R. B. Lechner, N. J. Gurll, D. G. Reynolds, and M. J. Brody:
Intracoronary naloxone potentiates catecholamine efficacy in canine hemorrhagic shock. Circ. Shock 13:64-65, 1984.
37. A. Kamhawy, T. Powell, N. J. Gurll, and D. G. Reynolds: Cardiovascular effects of naltrexone in canine hemorrhagic shock are dose dependent. Circ. Shock 13:45-46, 1984.
38. R. B. Lechner, N. J. Gurll, and D. G. Reynolds: Naloxone improves cardiovascular function in hemorrhagic shock by acting at cardiac opiate receptors. Fed. Proc. 44:1354, 1985.
39. B. E. Modin, E. Ganes, D. G. Reynolds and N. J. Gurll: Naloxone requires circulating catecholamines for efficacy in primate hemorrhagic shock. Fed. Proc. 44:1574, 1985.
40. N. J. Gurll, E. Ganes, and D. G. Reynolds: The central nervous system is involved in the cardiovascular responses to naloxone in canine endotoxic but not hemorrhagic shock. Circ. Shock 16:59, 1985.

Manuscripts

1. D. G. Reynolds, N. J. Gurll, T. Vargish, R. B. Lechner, A. I. Faden, and J. W. Holaday: Blockade of opiate receptors with

- naloxone improves survival and cardiac performance in canine endotoxic shock. *Circ. Shock* 7:39-48, 1980.
2. T. Vargish, D. G. Reynolds, N. J. Gurll, R. B. Lechner, J. W. Holaday, and A. I. Faden: Naloxone reversal of hypovolemic shock in dogs. *Circ. Shock* 7:31-38, 1980.
 3. N. J. Gurll, D. G. Reynolds, D. Coon, and S. S. Shirazi: Acute and chronic splanchnic blood flow responses to portacaval shunt in the normal dog. *Gastroenterology* 78:1432-1436, 1980.
 4. N. J. Gurll, K. Middleton, and E. Clark: Duodenal mucosal acid protection and its inhibition by aspirin and bile salt. *Surg. Forum* 31:131-134, 1980.
 5. R. E. Lind, N. J. Gurll, J. T. Jenkins, and D. G. Reynolds: Possible role of endorphins and opiate receptors in superior mesenteric artery occlusion shock. *Surg. Forum* 31:48-51, 1980.
 6. N. J. Gurll, D. G. Reynolds, and T. Vargish: Endorphins in the pathophysiology of hemorrhagic shock. *Adv. Physiol. Sci.* 26:213-214, 1981.
 7. J. A. Buckwalter, N. J. Gurll, and C. G. Thomas, Jr.: Malignancies of the thyroid in youth. *World J. Surg.* 5:15-25, 1981.
 8. N. J. Gurll, T. Vargish, D. G. Reynolds, and R. B. Lechner: Opiate receptors and endorphins in the pathophysiology of hemorrhagic shock. *Surgery* 89:364-369, 1981.
 9. N. J. Gurll and A. J. Damianos: The role of histamine and histamine receptors in the pathogenesis and treatment of erosive gastritis. *World J. Surg.* 5: 181-187, 1981.
 10. N. J. Gurll, J. W. Holcroft, P. Numann, D. G. Reynolds, R. S. Rhodes, R. P. Saik, F. T. Thomas, M. D. Tilson, and C. K. Zarins:

The Veterans Administration and academic surgery: A report from the Committee on Issues of the Association for Academic Surgery 1979 meeting. J. Surg. Res. 33:1-10, 1982.

11. N. Gurll, J. Harmon, and D. G. Reynolds: Histamine H_1 and H_2 receptor blockade does not maintain electrochemical gradients across canine gastric mucosa exposed to bile salt. Dig. Dis. Sci. 27:538-544, 1982.
12. N. J. Gurll, D. G. Reynolds, T. Vargish, and R. Lechner: Naloxone without transfusion prolongs survival and enhances cardiovascular function in hypovolemic shock. J. Pharmacol. Exp. Ther. 220:621-624, 1982.
13. N. J. Gurll, D. G. Reynolds, T. Vargish, and R. Lechner: Naltrexone improves survival rate and cardiovascular function in canine hemorrhagic shock. J. Pharmacol. Exp. Ther. 220:625-628, 1982.
14. T. Vargish, D. G. Reynolds, N. J. Gurll, E. M. Ganes, and S. A. Lutz: The interaction of corticosteroids and naloxone in canine hemorrhagic shock. J. Surg. Res. 32:289-295, 1982.
15. N. J. Gurll, R. Lechner, D. G. Reynolds, and J. Jenkins: Autonomic innervation of the heart is not critical for the hemodynamic responses to naloxone in hypovolemic dogs. Surg. Forum 33:241-244, 1982.
16. S. Anuras, F. A. Mitros, T. V. Nowak, V. V. Ionasescu, N. J. Gurll, J. Christensen, and J. B. Green: A familial visceral myopathy with external ophthalmoplegia and autosomal recessive transmission. Gastroenterology 84:346-353, 1983.

17. N. Gurll: Naloxone in endotoxic shock: Experimental models and clinical perspective. *Adv. Shock Res.* 10:63-71, 1983.
18. M. L. Patton, N. J. Gurll, D. G. Reynolds, and T. Vargish: Adrenalectomy abolishes and cortisol restores naloxone's beneficial effects on cardiovascular function and survival in canine hemorrhagic shock. *Circ. Shock* 10:317-327, 1983.
19. T. Vargish, N. J. Gurll, D. G. Reynolds, S. A. Lutz, and E. M. Ganes: Hemodynamic changes following corticosteroid and naloxone infusion in dogs subjected to hypovolemic shock without resuscitation, *Life Sci.* 33:489-493, 1983.
20. M.D. Owen, C.V. Gisolfi, D.G. Reynolds, and N.J. Gurll: Effects of central injections of D-ala²-met-enkephalinamide (DAME) in the monkey. *Peptides* 5:737-742, 1984.
21. L.B. Hunt, N.J. Gurll, and D.G. Reynolds: Dose-dependent effects of nalbuphine in canine hemorrhagic shock. *Circ. Shock* 13:307-318, 1984.
22. N.J. Gurll, A. Kamhawy, T. Powell and D.G. Reynolds: Dose-dependent effects of naltrexone on cardiovascular function and survival in canine hemorrhagic shock. *Surg. Forum* 35:22-24, 1984.
23. R.B. Lechner, N.J. Gurll, and D.G. Reynolds: Effects of naloxone on regional blood flow distribution in canine hemorrhagic shock. *Proc. Soc. Exp. Biol. Med.* 178:227-233, 1985.
24. R.B. Lechner, N.J. Gurll, and D.G. Reynolds: Role of the autonomic nervous system in mediating the response to naloxone in canine hemorrhagic shock. *Circ. Shock* 16:279-295, 1985.

25. R.B. Lechner, N.J. Gurll, and D.G. Reynolds: Naloxone potentiates the cardiovascular effects of catecholamines in canine hemorrhagic shock. *Circ. Shock* 16:347-361, 1985.
26. R.B. Lechner, N.J. Gurll, and D.G. Reynolds: Intra-coronary naloxone in hemorrhagic shock: Dose-dependent stereospecific effects. *Am. J. Physiol.* 249: H272-H277, 1985.

Book Chapters

1. N. J. Gurll: Endorphins in endotoxic shock. Chapter 12 in PATHO-PHYSIOLOGY OF ENDOTOXIN, ed. L.B. Hinshaw, Vol. 2 of HANDBOOK OF ENDOTOXIN, Ed. R. A. Proctor, Elsevier, Amsterdam, 1985.
2. R. B. Lechner, N.J. Gurll, and D.G. Reynolds: Endogenous opioids and cardiovascular shock. In CIRCULATORY SHOCK: BASIC AND CLINICAL IMPLICATIONS, (a volume of RESEARCH TOPICS IN PHYSIOLOGY), ed. H. F. Janssen and C. D. Barnes, Academic Press, New York, 1985.

PERSONNEL SUPPORTED BY THIS CONTRACT

Nelson J. Gurll, M.D. -----	No
David G. Reynolds, Ph.D. -----	salary
Thomas Vargish, M.D. -----	support
Carl V. Gisolfi, Ph.D. - partial salary	
Robert Lechner, M.D., Ph.D. (1985)	
Eric M. Ganes, B.S. - salary	
Thomas Smith, B.S. - salary	
Richard E. Lind, M.D. -----	Surgical
Stephen A. Lutz, M.D. -----	residents
Mary Lou Patton, M.D. -----	working
Lyle B. Hunt, M.D. -----	in
Brance E. Modin, M.D. -----	laboratory
M. D. Owen -----	Doctoral candidates working in
K. C. Kregel -----	Dr. Gisolfi's laboratory
Joseph Jenkins, M.D. -----	Worked in our
Ann Kamhawy -----	laboratories as
Tracy Powell -----	medical students
Aristotle Dimiancs -----	or undergraduates

DISTRIBUTION LIST

4 copies Commander
 Letterman Army Institute of
 Research (LAIR), Bldg. 1110
 ATTN: SGRD-ULZ-RC
 Presidio of San Francisco, CA 94129-6815

1 copy Commander
 US Army Medical Research and Development Command
 ATTN: SGRD-RMI-S
 Fort Detrick, Frederick, Maryland 21707-5012

12 copies Defense Technical Information Center (DTIC)
 ATTN: DTIC-DDAC
 Cameron Station
 Alexandria, VA 22304-6145

1 copy Dean
 School of Medicine
 Uniformed Services University of the
 Health Sciences
 4301 Jones Bridge Road
 Bethesda, MD 20814-4799

1 copy Commandant
 Academy of Health Sciences, US Army
 ATTN: AHS-CDM
 Fort Sam Houston, Texas 78234-6100

EMD
DATE
FILMED
3-1988
DTIC